Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action

Anna Francis¹, Colin Baigent³, T. Alp Ikizler⁵, Paul Cockwell⁴,⁵ and Vivekanand Jha⁶,⁷,⁸
¹School of Medicine, University of Queensland, Queensland, Australia; ²Medical Research Council Population Health Research Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK; ³Department of Medicine, Division of Nephrology and Hypertension, Vanderbilt University School of Medicine, Nashville, Tennessee, USA; ⁴Renal Medicine, Division of Medicine, Queen Elizabeth Hospital Birmingham, Birmingham, UK; ⁵Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK; ⁶Division of Medicine, George Institute for Global Health, India, University of New South Wales, New Delhi, India; ⁷Division of Medicine, School of Public Health, Imperial College, London, UK; and ⁸Division of Medicine, Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India

Correspondence: Anna Francis, Department of Nephrology, Level 12, Queensland Children’s Hospital, Stanley Street, South Brisbane, Queensland, Australia. E-mail: anna.francis@health.qld.gov.au

Kidney International (2021) 99, 791–793; https://doi.org/10.1016/j.kint.2021.02.003
KEYWORDS: COVID-19; dialysis; vaccination
Copyright © 2021, International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

The coronavirus disease 2019 (COVID-19) pandemic is causing extreme stress to many health systems and an ever-mounting death toll. Out of the darkness of the last 14 months comes a beacon of hope in the form of multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. To best utilize this precious resource, we must efficiently deploy vaccination to high-risk groups.

Providing equitable access to vaccines requires multiple considerations, including quantification of the risk of serious disease according to age and comorbidities, the safety and efficacy of the vaccines, and operational considerations relating to vaccine availability and administration. This editorial aims to highlight both the catastrophic risks of infection with SARS-CoV-2 and of subsequent death from COVID-19 in dialysis patients and the current failure to recognize these risks when considering priorities for COVID-19 vaccination. This is a “Call to Action” for policy makers worldwide to ensure prioritized designation of these patients in their countries.

People receiving dialysis treatment for end-stage kidney disease have specific circumstances that lead to an increased risk of SARS-CoV-2 infection. Most patients receive in-center hemodialysis (ICHD), which necessitates traveling to the dialysis center 3 times a week, attending for at least 3 to 4 hours, generally surrounded by numerous other patients as well as staff. Therefore, these patients cannot self-isolate. As an example, patients receiving ICHD in Flanders, France, and in New York, New York, USA, were 5 to 16 times more likely to be diagnosed with COVID-19 disease compared with the general population.¹,³–⁵,⁷–⁸,¹ⁱ The higher risk of death once infected for dialysis patients may be due to impaired immune function and an increased prevalence of other well-established risk factors for death from COVID-19, including hypertension, obesity, diabetes, and heart disease.¹,³–⁵,⁷–⁸,¹¹–¹³ In addition, the prevalence of kidney failure is higher in Black, Asian, and minority ethnic groups and individuals with low socioeconomic status, groups that have a higher disease burden from COVID-19, where reported. The increased incidence of SARS-CoV-2 infection and increased mortality when infected have resulted in widespread death, with 1 in 33 ICHD patients in the United Kingdom dying from COVID-19 in the first wave.³ Population-based analysis shows age-matched relative risk of death from COVID-19 for an ICHD patient compared with the general population ranges from 432 for a 20- to 39-year-old patient to around 10 for a patient aged >80 years.⁵

To date, therefore, there is clear evidence that nonelderly patients on dialysis have experienced exceptionally high mortality rates, in most cases equaling or exceeding rates observed in elderly patients in their regions (i.e., those...
aged >80 years), who (properly) have generally been given priority for vaccination. There is a common misconception that most dialysis patients are very elderly and thus will automatically qualify for immediate vaccination. In fact, dialysis patients are on average younger (mean age, 65–70 years) than the classic high-risk group of those aged >85 years, with large potential gains in life years saved by the vaccine. In many countries, patients on dialysis have been placed on equal priority with risk groups, such as those with obesity, heart disease, or diabetes or smokers, which represent a large proportion of the population. Immunizing this enormous group will take time. We argue patients on dialysis should be prioritized, as they are at much greater risk of acquiring COVID-19 than these aforementioned groups and, once infected, their risk of death due to COVID-19 is substantially greater.

There are also underrecognized indirect effects of the SARS-CoV-2 pandemic in dialysis patients. The constant threat of death from contracting SARS-CoV-2, particularly at a dialysis session, has led to widespread fear and anxiety for people on dialysis. For this reason, people may skip dialysis sessions, increasing the risk of death, even in the absence of COVID-19 disease. In addition, the general health system strain and the complexities of isolating SARS-CoV-2-positive ICHD patients during surges forced some dialysis units to decrease the number of weekly sessions from 3 to 2, further impacting patient care.

There is some nihilism within the medical community regarding vaccination of dialysis patients due to scarce data on the safety and effectiveness of SARS-CoV-2 vaccines in this population. Remarkably, no dialysis patient has been reported to have been included in any of the vaccine trials globally. This obvious “renalism” should not be allowed to translate into vaccination efforts. Limited data from New York report all surviving patients with polymerase chain reaction–confirmed COVID-19 disease had SARS-CoV-2 IgG detectable around 2 months post infection, suggesting seroconversion from a vaccine will occur. Vaccinations against hepatitis B, influenza, and pneumococcal disease are routinely recommended in people receiving maintenance hemodialysis. Seroconversion rates of 33% to 80% are reported for the influenza vaccine, with older patients less likely to seroconvert. Some people, especially elderly patients, require larger doses to effectively seroconvert, and this should be monitored for the SARS-CoV-2 vaccine, as adapted immunization protocols may be required. There is an urgent need to initiate detailed studies of the efficacy of SARS-CoV-2 vaccination among patients with kidney failure (and those who have a functioning kidney transplant).

Dialysis patients are high health care utilizers, allowing for efficient communication regarding the vaccine and any vaccine hesitancy. Frequent in-center attendance eases barriers of vaccine delivery and administration, which can be provided during routine dialysis sessions. The opportunity for mass vaccination at dialysis units provides an unprecedented opportunity for operational efficiency, as all

### Table 1 | Urgent reasons to prioritize vaccination for dialysis patients

| Reason | Risk estimates | High-risk groups |
|---|---|---|
| Increased risk of SARS-CoV-2 infection | 5–20 times more likely to be infected than the general population. | In-center hemodialysis |
| | 5%–20% symptomatic and 28%–36% with serologic evidence of infection during the first wave. | Diabetes |
| Increased case fatality from COVID-19 | 16%–32% case fatality. | Obesity |
| | 50% mortality for those in ICU. | Lack of private transportation |
| | 1.3–2.3 times higher case fatality than hospitalized patients with COVID-19 but no CKD. | Hypertension |
| High risk of infection and high risk of death once infected | Relative risk of death compared with age-matched general population. | Obesity |
| translates to high(est) community risk group for death | 20–39 yr: 432 | Older people |
| | 40–59 yr: 94 | Heart disease |
| | 60–79 yr: 33 | |
| | >80 yr: ~10 | |

CKD, chronic kidney disease; COVID-19, coronavirus disease 2019; ICU, intensive care unit; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
attendees at a dialysis unit could be administered their first dose within 2 days. This would, in turn, protect the families of dialysis patients from exposure to SARS-CoV-2.

Administrators must use evidence-based prioritization for vaccination rather than “one size fits all” approach for patients at the highest risk. As dialysis patients are at the highest risk from COVID-19 (Table 1), vaccinating dialysis patients may have the highest relative impact of all health care groups, through reducing infections, mortality, and burden on the health care system. Particular considerations are required for the delivery of vaccination in resource-constrained countries.

People receiving maintenance dialysis report profound psychosocial stress related to the pandemic and anxiously await vaccination. The International Society of Nephrology urgently calls for the immediate prioritization of dialysis patients worldwide to receive the life-saving treatment of the SARS-CoV-2 vaccine. National and regional stakeholders can advocate for priority access to vaccination for dialysis patients and assist efficient implementation of a vaccine program that will protect the most vulnerable: those on dialysis.

DISCLOSURE
All the authors declared no competing interests.

ACKNOWLEDGEMENTS
The authors gratefully acknowledge the assistance of Drs. Alan Salama, Katie Vinen, and Aakash Shingada in the creation of this article and visual abstract.

SUPPLEMENTARY MATERIAL
Supplementary File (PDF)
Supplementary References.

REFERENCES
1. De Meester J, De Bacquer D, Naesens M, et al. Incidence, characteristics, and outcome of COVID-19 in adults on kidney replacement therapy: a regionwide registry study. J Am Soc Nephrol. 2021;32:385–396.
2. Alberici F, Delbarba E, Manenti C, et al. A report from the Brescia Renal COVID Task Force on the clinical characteristics and short-term outcome of hemodialysis patients with SARS-CoV-2 infection. Kidney Int. 2020;98:20–26.
3. Ng JH, Hirsch JS, Wanchoo R, et al. Outcomes of patients with end-stage kidney disease hospitalized with COVID-19. Kidney Int. 2020;98:1530–1539.
4. Jager KJ, Kramer A, Chesnaye NC, et al. Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020;98:1540–1548.
5. Savino M, Casula A, Santhakumaran S, et al. Sociodemographic features and mortality of individuals on haemodialysis treatment who test positive for SARS-CoV-2: a UK Renal Registry data analysis. PLoS One. 2020;15:e0241263.